OptimizeRx’s (OPRX) “Buy” Rating Reiterated at Lake Street Capital

Lake Street Capital reaffirmed their buy rating on shares of OptimizeRx (NASDAQ:OPRX) in a research note published on Tuesday,Benzinga reports. They currently have a $11.00 target price on the stock.

OPRX has been the topic of several other reports. William Blair reaffirmed an “outperform” rating on shares of OptimizeRx in a research report on Thursday, November 14th. JMP Securities cut their price objective on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a report on Thursday, November 14th. Barclays lowered their target price on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a research note on Thursday, November 14th. Stephens assumed coverage on shares of OptimizeRx in a research note on Friday, December 20th. They set an “equal weight” rating and a $5.50 price target on the stock. Finally, Royal Bank of Canada lowered their price objective on shares of OptimizeRx from $14.00 to $7.00 and set an “outperform” rating for the company in a research note on Thursday, November 14th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.19.

OptimizeRx Price Performance

NASDAQ OPRX opened at $5.17 on Tuesday. The firm’s fifty day simple moving average is $5.25 and its two-hundred day simple moving average is $7.65. The firm has a market capitalization of $95.24 million, a P/E ratio of -3.89 and a beta of 1.34. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. OptimizeRx has a 12-month low of $3.78 and a 12-month high of $16.65.

Insider Activity at OptimizeRx

In related news, CEO William J. Febbo bought 20,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average cost of $5.01 per share, with a total value of $100,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 601,253 shares in the company, valued at approximately $3,012,277.53. The trade was a 3.44 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 6.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On OptimizeRx

Several hedge funds have recently bought and sold shares of the stock. Barclays PLC increased its holdings in shares of OptimizeRx by 358.5% during the 3rd quarter. Barclays PLC now owns 26,934 shares of the company’s stock valued at $208,000 after purchasing an additional 21,060 shares in the last quarter. Bullseye Asset Management LLC grew its position in OptimizeRx by 55.6% during the third quarter. Bullseye Asset Management LLC now owns 214,046 shares of the company’s stock valued at $1,652,000 after buying an additional 76,458 shares during the period. BNP Paribas Financial Markets increased its holdings in OptimizeRx by 189.2% in the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after buying an additional 2,414 shares in the last quarter. Quest Partners LLC raised its position in shares of OptimizeRx by 15,965.6% in the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after acquiring an additional 9,739 shares during the period. Finally, Greenwood Capital Associates LLC boosted its stake in shares of OptimizeRx by 8.0% during the 3rd quarter. Greenwood Capital Associates LLC now owns 67,356 shares of the company’s stock worth $520,000 after acquiring an additional 4,999 shares in the last quarter. Hedge funds and other institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.